Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Profound Medical ( (TSE:PRN) ) is now available.
Profound Medical Corp. has upsized its previously announced private placement to raise up to US$6.45 million through the issuance of as many as 921,428 common shares at US$7.00 per share, in order to accommodate demand from a long-term existing investor. The financing, expected to close by December 30, 2025 and subject to a standard four-month-plus-one-day hold period, will provide additional capital to expand sales and marketing, fund working capital and R&D, support potential strategic transactions and general corporate purposes, strengthening the company’s balance sheet as it seeks to scale commercialization of its MRI-guided, incision-free therapeutic platforms in competitive global medtech markets.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its lead technology, TULSA-PRO, enables the TULSA Procedure, a one-session, radiation- and incision-free treatment for a broad spectrum of prostate diseases, while its Sonalleve platform targets indications such as uterine fibroids, adenomyosis, bone metastasis pain, desmoid tumors and osteoid osteoma, with regulatory clearances in North America, Europe and China and exploratory work in additional cancer applications.
Average Trading Volume: 20,443
Technical Sentiment Signal: Buy
Current Market Cap: C$302.8M
Find detailed analytics on PRN stock on TipRanks’ Stock Analysis page.